South Korean Biotech 2023, page-27

If all of these events are a miss, I'm out. There are more exciting speccies out there. There was a very interesting question posted yesterday that got a few thumbs up but no actual responses.

Something about at what point are we no longer classed as 'early stage' given it's been about 15 years.

I find that a very relevant question, one which I think was overlooked and I'd like to see a few of our bigger, longer holders offer up their thoughts. I know some of our trials are still phase 1, but others we've been working on for years it seems. I think at some point, the penny has to drop one way or another. I've only been a holder for 2.5 years and already getting a bit antsy, I guess partly because I'm now in the red after my initial buy price of 11c and averaging down.

And to answer your question, given PAA has been around that long and working on certain things for quite some time, I'd say it's fair to blame management already. IMO only. I still have faith the science will hold up though.